Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.

Publication Title

Cancer cell

Authors

David Hsiehchen
Andrew Elliott
Joanne Xiu
Andreas Seeber
Wafik El-Deiry
Emmanuel S Antonarakis
Stephanie L Graff
Michael J Hall
Hossein Borghaei
Dave Hoon, Department of Translational Molecular Medicine, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.Follow
Stephen V Liu
Patrick C Ma
Rana R McKay
Trisha Wise-Draper
John Marshall
George W Sledge
David Spetzler
Hao Zhu

Document Type

Article

Publication Date

12-9-2024

Keywords

california; santa monica; pni; Humans; Programmed Cell Death 1 Receptor; Mutation; Neoplasms; Immune Checkpoint Inhibitors; Lymphocytes, Tumor-Infiltrating; Lymphocyte Activation; Immunotherapy; B7-H1 Antigen

Abstract

Analysis of 27,810 patients with advanced cancers treated with anti-PD-1/L1 therapies shows that immune gene signatures or immune cell infiltration is not universally associated with mutation burden or long-term survivors after immunotherapies across cancer entities. Thus, immunological stratification of tumors has limited bearing on the immunogenicity of tumors or immunotherapy outcomes.

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

Specialty/Research Institute

Hematology

DOI

10.1016/j.ccell.2024.10.017